- Home
- LPTX vs EVGN Comparison
LPTX vs EVGN Comparison
Compare LPTX & EVGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LPTX
- EVGN
- Stock Information
- Founded
- LPTX 2011
- EVGN 1999
- Country
- LPTX United States
- EVGN Israel
- Employees
- LPTX N/A
- EVGN N/A
- Industry
- LPTX Biotechnology: Biological Products (No Diagnostic Substances)
- EVGN Agricultural Chemicals
- Sector
- LPTX Health Care
- EVGN Industrials
- Exchange
- LPTX Nasdaq
- EVGN Nasdaq
- Market Cap
- LPTX 11.1M
- EVGN 11.6M
- IPO Year
- LPTX N/A
- EVGN N/A
- Fundamental
- Price
- LPTX $0.29
- EVGN $1.24
- Analyst Decision
- LPTX Hold
- EVGN Strong Buy
- Analyst Count
- LPTX 1
- EVGN 1
- Target Price
- LPTX N/A
- EVGN $3.50
- AVG Volume (30 Days)
- LPTX 2.0M
- EVGN 55.7K
- Earning Date
- LPTX 08-14-2025
- EVGN 08-19-2025
- Dividend Yield
- LPTX N/A
- EVGN N/A
- EPS Growth
- LPTX N/A
- EVGN N/A
- EPS
- LPTX N/A
- EVGN N/A
- Revenue
- LPTX N/A
- EVGN $9,444,000.00
- Revenue This Year
- LPTX N/A
- EVGN N/A
- Revenue Next Year
- LPTX N/A
- EVGN $63.64
- P/E Ratio
- LPTX N/A
- EVGN N/A
- Revenue Growth
- LPTX N/A
- EVGN N/A
- 52 Week Low
- LPTX $0.22
- EVGN $0.95
- 52 Week High
- LPTX $4.79
- EVGN $3.35
- Technical
- Relative Strength Index (RSI)
- LPTX 46.11
- EVGN 46.32
- Support Level
- LPTX $0.28
- EVGN $1.26
- Resistance Level
- LPTX $0.31
- EVGN $1.33
- Average True Range (ATR)
- LPTX 0.04
- EVGN 0.07
- MACD
- LPTX 0.00
- EVGN -0.00
- Stochastic Oscillator
- LPTX 39.39
- EVGN 20.48
About LPTX Leap Therapeutics Inc.
Leap Therapeutics Inc is a biopharmaceutical company developing novel biomarker-targeted antibody therapies designed to treat patients with cancer by inhibiting fundamental tumor-promoting pathways, targeting cancer-specific cell surface molecules, and harnessing the immune system to attack cancer cells. The company's key clinical-stage drug candidate is sirexatamab (DKN-01), which targets Dickkopf-related protein 1 (DKK1) and is being studied in a clinical trial in patients with colorectal cancer. In addition, it also has a preclinical program to develop a proprietary monoclonal antibody, called FL-501 which works by inhibiting the GDF-15 protein.
About EVGN Evogene Ltd
Evogene Ltd is a computational biology company targeting to revolutionize product development for life-science based industries, including human health, agriculture, and industrial applications. The company established its technology, the Computational Predictive Biology (CPB) platform. The CPB platform is designed to computationally discover and develop life-science products based on microbes, small molecules, and genetic elements as the core components for such products. It holds several subsidiaries utilizing the CPB platform for the development of human microbiome-based therapeutics, medical cannabis, ag-biologicals, ag-chemicals, seed traits, and ag-solutions for castor oil production. It generates maximum revenue from the Agriculture segment, followed by Industry.